Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* 

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL
OMB Number: 3235-0287

OMB Number:	3235-0287
Estimated average burd	den
hours per response:	0.5

()		1 100	or Section 30(h) of the Investment Company Act of 1940			,		
1. Name and Addree <u>SACHS BRU</u> (Last)	ss of Reporting Perso	n* (Middle)	2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA</u> [ VRTX ]		tionship of Reporting Pers all applicable) Director Officer (give title below)	on(s) to Issuer 10% Owner Other (specify below)		
C/O VERTEX PHARMACEUTICALS INCORPORATED			3. Date of Earliest Transaction (Month/Day/Year) 05/07/2020					
50 NORTHERN AVENUE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)				X	Form filed by One Repo	rting Person		
BOSTON	MA	02210			Form filed by More than Person	One Reporting		
(City)	(State)	(Zip)						

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	05/07/2020		М		22,500	A	\$59.55	33,710	D	
Common Stock	05/07/2020		М		22,500	A	\$81.54	56,210	D	
Common Stock	05/07/2020		S <sup>(1)</sup>		2,600	D	\$267.5 <sup>(2)(3)</sup>	53,610	D	
Common Stock	05/07/2020		S <sup>(1)</sup>		11,568	D	\$268.65 <sup>(3)(4)</sup>	42,042	D	
Common Stock	05/07/2020		<b>S</b> <sup>(1)</sup>		15,751	D	\$269.53 <sup>(3)(5)</sup>	26,291	D	
Common Stock	05/07/2020		S <sup>(1)</sup>		5,889	D	\$270.49(3)(6)	20,402	D	
Common Stock	05/07/2020		<b>S</b> <sup>(1)</sup>		6,232	D	\$271.63(3)(7)	14,170	D	
Common Stock	05/07/2020		<b>S</b> <sup>(1)</sup>		2,960	D	\$272.46 <sup>(3)(8)</sup>	11,210	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	Transaction of			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying		8. Price of Derivative Security	9. Number of derivative Securities	10. Ownership Form:	11. Nature of Indirect Beneficial	
(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	8)		Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				Derivative Security (Instr. 3 and 4)		(Instr. 5)	Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$59.55	05/07/2020		М			22,500	(9)	05/31/2022	Common Stock	22,500	\$0.00	0	D	
Stock Option (Right to Buy)	\$81.54	05/07/2020		М			22,500	(9)	05/31/2023	Common Stock	22,500	\$0.00	0	D	

## Explanation of Responses:

1. Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$267.50 (range \$267.06 to \$268.03).

3. Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of \$268.65 (range \$268.06 to \$269.03).

5. Open market sales reported on this line occurred at a weighted average price of \$269.53 (range \$269.06 to \$270.04).

6. Open market sales reported on this line occurred at a weighted average price of \$270.49 (range \$270.09 to \$271.08).

7. Open market sales reported on this line occurred at a weighted average price of \$271.63 (range \$271.17 to \$272.14).

Open market sales reported on this line occurred at a weighted average price of \$272.46 (range \$272.21 to \$272.94).
 Fully vested.

Remarks:

Remarks

<u>/s/ Sabrina Yohai, Attorney-in-</u> <u>Fact</u> \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.